Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Classification Challenge of Pediatric Spondylarthritis

Robert A. Colbert, MD, PhD  |  Issue: April 2010  |  April 1, 2010

Spondylarthritis (SpA) refers to a group of disorders with overlapping clinical features, estimated to affect between 0.5% and 2% of the population.1,2 Most often included in the SpA group are ankylosing spondylitis (AS), which constitutes about half of SpA, reactive arthritis, the arthritides associated with psoriasis and inflammatory bowel disease, and undifferentiated SpA. Although the majority of SpA starts in the third or fourth decade of life, a significant proportion of patients (10–20%) begin to experience symptoms during childhood. In pediatric rheumatology clinics, SpA accounts for up to 15–20% of the cases of inflammatory arthritis, with oligoarthritis, polyarthritis, and systemic juvenile arthritis accounting for the majority.

The most severe and often most debilitating form of SpA, AS, involves the axial skeleton and causes inflammation in the sacroiliac joints, vertebral bodies and intervertebral discs, and facet joints. Structural remodeling results in pathological bone formation in the form of osteophytes and syndesmophytes. These structures bridge vertebral bodies, leading to reduced spinal mobility and eventual fusion. At its earliest stages, SpA is often undifferentiated (i.e., lacks defining clinical or radiographic features) and may not involve the spine. The lack of axial involvement and related symptoms such as inflammatory back pain is particularly notable in children, who instead have a greater tendency to develop enthesitis and arthritis in the hips and other large joints of the lower extremities.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Progression from undifferentiated SpA to AS is unpredictable in adults and children, and there is often a long lag period (8–11 years) between the onset of symptoms and a diagnosis of AS.4-6 Prompt recognition and management of early axial SpA, whether presenting in children or adults, is our best hope to alter the disease course and improve long-term outcomes. However, identifying those patients with undifferentiated SpA who are most likely to develop axial disease and AS, as well as appropriate pathways and targets for therapeutic intervention, remain important unmet needs in SpA.

Colored X-ray of the thoracic and lumbar spine in a patient suffering from ankylosing spondylitis.
Colored X-ray of the thoracic and lumbar spine in a patient suffering from ankylosing spondylitis.

The Classification of SpA

Recognizing SpA in children and distinguishing it from other forms of juvenile arthritis can be a challenge. Rosenberg and Petty recognized the need for specific classification criteria in the early 1980s and proposed the concept of the seronegative enthesopathy and arthropathy (SEA) syndrome. This syndrome has been defined as enthesitis with arthralgia or arthritis in children less than 17 years of age who also lack rheumatoid factor (RF) and antinuclear antibodies.7 The features of the SEA syndrome helped distinguish SpA from juvenile arthritis, classified at the time as juvenile rheumatoid or juvenile chronic arthritis, without relying on evidence of axial involvement.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Axial SpondyloarthritisConditionsPediatric Conditions Tagged with:Diagnostic CriteriaJuvenile idiopathic arthritisPathogenesisPediatricPediatric SpondyloarthritisTreatment

Related Articles

    Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis

    May 1, 2014

    New research clarifies terminology used for diagnosis, but questions remain around epidemiology, genetics and management of patients with axial skeletal inflammation

    Top Research in Axial Spondyloarthritis Presented at ACR Convergence 2022

    November 18, 2022

    PHILADELPHIA—Approximately 100 research abstracts on axial spondyloarthritis (axSpA) were accepted for presentation at ACR Convergence 2022. It is exciting to see a wealth of research on axSpA being undertaken worldwide. Here, we highlight important points from 10 of these studies. 1. Abstract 0378: Prevalence of Axial Spondyloarthritis (axSpA) in Patients Treated for Chronic Back Pain…

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    How HLA-B27 Research Landmarks, Advances Relate to Ankylosing Spondylitis Pathogenesis

    July 13, 2016

    The mechanistic link between human leukocyte antigen B27 (HLA-B27) and ankylosing spondylitis (AS) is one of the great enigmas in rheumatology. The introduction of biological therapies that target tumor necrosis factor (TNF) or the interleukin (IL) 23/IL-17A axis has had a major impact on the quality of life for many patients with AS, and one…

    Data Accumulate to Suggest HLA-B27 Status May Drive Axial Phenotype in SpA

    May 20, 2022

    HLA-B27 may be a phenotypic expression of axial spondyloarthritis (SpA), according to a large international study. The study found patients with axial SpA who were positive for HLA-B27 had more severe radiographic damage than those who were negative for HLA-B27, and three quarters of study patients with ankylosis spondyloarthritis were HLA-B27 positive.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences